Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 13, 2020 / 03:00PM GMT
Release Date Price: €21.76 (-3.89%)
Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

All right. Good morning. Looking forward to today's discussion around the work we're doing here at Denali Therapeutics. I'm Ryan Watts. I'm the CEO of Denali Therapeutics. And for those of you that have joined the call today, there will be a slide deck distributed on the webcast, and I ask that you look to the bottom left-hand corner for the slide numbers. I will reference those slide numbers as I go through today's presentation.

So as a reminder, Denali -- starting with Slide 2, Denali was founded to work on neurodegenerative diseases, and our purpose is to defeat degeneration. You'll see on this slide, basically 4 major areas: rare neurodegenerative diseases, ALS, Parkinson's and Alzheimer's. And in fact, we have either ongoing or completed clinical trials in all 4 of these areas. I will share with you today some of the data that we've generated in Parkinson's disease as well as an emphasis on our approach for engineering large molecules for rare neurodegenerative diseases and also beyond in Alzheimer's disease

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot